Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Michaud, Veronique ^a   Frappier, Martin ^a   Dumas, Marie Christine ^a   Turgeon, Jacques ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 4A11; MESSENGER RNA; VERAPAMIL; ANTIARRHYTHMIC AGENT; CYTOCHROME P 450 CYP2C SUBFAMILY; CYTOCHROME P-450 CYP2C SUBFAMILY; ISOENZYME;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; GENE EXPRESSION; GENE IDENTIFICATION; HEART; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISCHEMIC HEART DISEASE; LIVER CELL; METABOLITE; MICROSOME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; STEREOCHEMISTRY; DRUG EFFECT; FEMALE; HEART VENTRICLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; METABOLISM; METHODOLOGY; STEREOISOMERISM;

ANTI-ARRHYTHMIA AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HEART VENTRICLES; HUMANS; ISOENZYMES; MALE; MICROSOMES, LIVER; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEREOISOMERISM; VERAPAMIL;

EID: 78650798184     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015666     Document Type: Article

References (40)

1. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34: 83-448.
2. Zordoky BN, El-Kadi AO (2007) H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. J Pharmacol Toxicol Methods 56: 317-322.
3. Thum T, Borlak J (2000) Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. Br J Pharmacol 130: 1745-1752.
4. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, et al. (1997) Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272: 12551-12559.
5. Aboutabl ME, Zordoky BN, El-Kadi AO (2009) 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol 158: 1808-1819.
6. Abraham NG, Pinto A, Levere RD, Mullane K (1987) Identification of heme oxygenase and cytochrome P-450 in the rabbit heart. JMol Cell Cardiol 19: 73-81.
7. Stegeman JJ, Woodin BR, Klotz AV, Wolke RE, Orme-Johnson NR (1982) Cytochrome P-450 and monooxygenase activity in cardiac microsomes from the fish Stenotomus chrysops. Mol Pharmacol 21: 517-526.
8. Messina A, Nencioni S, Gervasi PG, Gotlinger KH, Schwartzman ML, et al. (2010) Molecular cloning and enzymatic characterization of sheep CYP2J. Xenobiotica 40: 109-118.
9. Messina A, Chirulli V, Gervasi PG, Longo V (2008) Purification, molecular cloning, heterologous expression and characterization of pig CYP1A2. Xenobiotica 38: 1453-1470.
10. Thum T, Borlak J (2000) Gene expression in distinct regions of the heart. Lancet 355: 979-983.
11. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC (1996) Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271: 3460-3468.
12. Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, et al. (2007) Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35: 682-688.
13. Sidorik L, Kyyamova R, Bobyk V, Kapustian L, Rozhko O, et al. (2005) Molecular chaperone, HSP60, and cytochrome P450 2E1 co-expression in dilated cardiomyopathy. Cell Biol Int 29: 51-55.
14. Elbekai RH, El-Kadi AO (2006) Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112: 564-587.
15. Fleming I (2001) Cytochrome p450 and vascular homeostasis. Circ Res 89: 753-762.
16. Payne AH, Hales DB (2004) Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 25: 947-970.
17. Kroetz DL, Zeldin DC (2002) Cytochrome P450 pathways of arachidonic acid metabolism. Curr Opin Lipidol 13: 273-283.
18. Theken KN, Lee CR (2007) Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. Pharmacogenomics 8: 1369-1383.
19. Satoh M, Matter CM, Ogita H, Takeshita K, Wang CY, et al. (2007) Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation 115: 3197-3204.
20. Dubey RK, Jackson EK, Gillespie DG, Rosselli M, Barchiesi F, et al. (2005) Cytochromes 1A1/1B1-and catechol-O-methyltransferase-derived metabolites mediate estradiol-induced antimitogenesis in human cardiac fibroblast. J Clin Endocrinol Metab 90: 247-255.
21. Thum T, Borlak J (2002) Testosterone, cytochrome P450, and cardiac hypertrophy. Faseb J 16: 1537-1549.
22. Hunter AL, Bai N, Laher I, Granville DJ (2005) Cytochrome p450 2C inhibition reduces post-ischemic vascular dysfunction. Vascul Pharmacol 43: 213-219.
23. Granville DJ, Tashakkor B, Takeuchi C, Gustafsson AB, Huang C, et al. (2004) Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors. Proc Natl Acad Sci U S A 101: 1321-1326.
24. Fischer D, Landmesser U, Spiekermann S, Hilfiker-Kleiner D, Hospely M, et al. (2007) Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur J Heart Fail 9: 770-775.
25. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, et al. (2004) Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95: 506-514.
26. Walles M, Thum T, Levsen K, Borlak J (2002) Verapamil: new insight into the molecular mechanism of drug oxidation in the human heart. J Chromatogr A 970: 117-130.
27. Earley S, Pastuszyn A, Walker BR (2003) Cytochrome p-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. Am J Physiol Heart Circ Physiol 285: H127-136.
28. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, et al. (2005) Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxiainduced endothelial cell migration and angiogenesis. J Cell Sci 118: 5489-5498.
29. Hunt CM, Westerkam WR, Stave GM (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44: 275-283.
30. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, et al. (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38: 978-988.
31. Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, et al. (2008) 4Betahydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 18: 201-208.
32. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, et al. (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 348: 332-337.
33. Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M (1995) Cytochromes of the P450 2C subfamily are the major enzymes involved in the Odemethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 353: 116-121.
34. Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW (1999) Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47: 545-552.
35. Shen L, Fitzloff JF, Cook CS (2004) Differential enantioselectivity and productdependent activation and inhibition in metabolism of verapamil by human CYP3As. Drug Metab Dispos 32: 186-196.
36. Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M (1984) Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of Land D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol 18: 733-740.
37. Raschack M (1976) Relationship of antiarrhythmic to inotropic activity and antiarrhythmic qualities of the optical isomers of verapamil. Naunyn Schmiedebergs Arch Pharmacol 294: 285-291.
38. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
39. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
40. Wang YH, Jones DR, Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32: 259-266.